Global Vaccine and Immunization Research Forum 2023 Agenda
The Global Vaccine and Immunization Research Forum 2023, scheduled for March 28-30 at Grand Hyatt, Incheon, Korea, will feature keynote speakers, plenary sessions, workshops, and discussions on various topics related to vaccine research, development, and global health. The agenda includes sessions on COVID-19 vaccines, future pandemic preparedness, special populations, new technologies, optimizing vaccine regimens, and more. Participants will engage with experts to explore ways to address global health challenges through innovative vaccine solutions.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. Download presentation by click this link. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
E N D
Presentation Transcript
Global Vaccine and Immunization Research Forum 2023 Grand Hyatt, Incheon, Republic of Korea 28 30 March 2023 Tuesday 28 March 07:30 Registration opens 08:30 - 08:45 Welcome and Opening Remarks 08:45 - 09:15 Keynote 1: Barney Graham 09:15 - 10:45 P1 From GVAP to IA2030: Roles of vaccine R&D to enable success 10:45 - 11:15 Break 11:15 - 12:45 P2 Lessons from COVID-19 vaccines and future pandemic preparedness 12:45 - 14:00 Lunch Ballroom ABC (East Tower) W1 Vaccines for special populations W2 Novel vaccine platforms W3 Regional manufacturing 14:00 - 15:30 15:30 - 16:00 Break 16:00 - 16:15 Workshop Reports 16:15 - 17:45 P3 Current status of R&D for HIV, TB, Malaria, and Universal Influenza vaccines 17:45 - 18:30 Break 18:30 - 19:30 Reception and Poster session 1 (odd-numbered posters, see pages 8-9) Wednesday 29 March 08:30 - 08:45 Introduction to Day 2 Keynote 2: Hee-ChangJang, National Institute of Health, Korea and Jerome Kim, International Vaccine Institute (IVI) 08:45 - 09:15 09:15 - 10:45 P4 Quantifying the value of vaccines beyond mortality 10:45 - 11:15 Break W4 Mucosal immunity and vaccines W5 Intersection of markets, value, and access policy W6 Implementation research to inform immunization programs 11:15 - 12:45 12:45 - 14:00 Lunch Ballroom ABC (East Tower) 14:00 - 14:15 Workshop Reports 14:15 - 15:45 P5 Innovating to find and reach Zero-Dose Children 15:45 - 16:15 Break 16:15 - 17:45 P6 Vaccine technologies for equity 17:45 - 18:30 Break 18:30 - 19:30 Reception and Poster session 2 (even-numbered posters, see pages 8-9) Thursday 30 March 08:30 - 08:45 Introduction to Day 3 08:45 - 10:15 P7 Optimizing vaccine regimens 10:15 - 10:45 Break 10:45 - 12:15 W7 New vaccines on the horizon W8 Select poster highlights W9 Addressing low uptake 12:30 - 12:45 Workshop Reports 12:45 - 13:45 P8 Reflections and closing remarks: Progress and the path forward 13:45 Close of meeting - lunch available following the close
Global Vaccine and Immunization Research Forum 2023 Grand Hyatt, Incheon, Republic of Korea 28 30 March 2023 Day 1 Plenary Sessions Grand Ballroom (West Tower) Welcome and Opening Remarks B.F. Lee Hall, US National Institutes of Allergy and Infectious Diseases (NIAID, chair) Katherine O Brien, World Health Organization (WHO)* Youngmee Jee, Korea Disease Control and Prevention Agency 08:30 - 08:45 Keynote 1: Barney Graham title to be announced 08:45 - 09:15 P1 From GVAP to IA2030: Roles of vaccine R&D to enable success Lee Hall, NIAID (chair) Lee Hall, NIAID Overview of GVAP and IA2030 Noni MacDonald, Dalhousie U. GVAP: Lessons Learned Helen Matzger, Bill & Melinda Gates Foundation (BMGF) Looking Ahead: Themes that will influence the R&D agenda Kwaku Poku Asante, Kintampo Health Research Centre IA2030 Strategic Priority 7: Research & Innovation: Overview and Goals Birgitte Giersing, WHO Partnering with regions and countries to identify priority pathogens for vaccines as part of SP7 09:15 - 10:45 10:45 - 11:15 Break P2 Lessons from COVID-19 vaccines and future pandemic preparedness Charlie Weller, Wellcome (chair) Ana Maria Henao Restrepo, WHO* Research & innovation: Outbreaks preparedness & response Melanie Saville, Coalition for Epidemic Preparedness Innovations (CEPI) CEPI s Lessons learnt from COVID-19 pandemic response, and the 100-day mission for pandemic preparedness Gustavo Santos, International Vaccine Institute (IVI) Regulatory Perspective: Brazil Tonya Villafana, AstraZeneca Lessons learned from an industry R&D perspective Additional panelists: Dicky Akanmori, U. Ghana, Karin Bok, US National Institutes of Health (NIH), and Martin Friede, WHO 11:15 - 12:45 12:45 - 14:00 Lunch Ballroom ABC (East Tower) Concurrent workshops see next page 14:00 - 15:30 15:30 - 16:00 Break Workshop Reports Carolyn Deal, NIAID W1 Vaccines for special populations Sue Ann Clemens, Oxford U. and Max Silverman, BMGF W2 Novel vaccine platforms Martin Friede, WHO W3 Regional manufacturing perspectives and opportunities 16:00 - 16:15 P3 Current status of R&D for HIV, Tuberculosis, Malaria, and Universal Influenza vaccines Annie Mo, NIH/NIAID and Jerome Kim, IVI (chairs) Ashley Birkett, PATH Malaria Vaccine R&D Mark Hatherill, South African Tuberculosis Vaccine Initiative TB Vaccine R&D Shan Lu, China National Medical Center for Infectious Diseases HIV vaccine Update Punnee Pitisuttithum, Mahidol U. Current Status of Universal Influenza Vaccine R&D Additional panelist: Lynda Stuart, BioNTech 16:15 - 17:45 17:45 - 18:30 Break Reception and Poster session 1 (odd-numbered posters) Martin Friede, WHO (chair) Mahima Datla, Biological E, and Rino Rappuoli, Fondazione Biotecnopolo di Siena 18:30 - 19:30 *recorded presentation 2
Global Vaccine and Immunization Research Forum 2023 Grand Hyatt, Incheon, Republic of Korea 28 30 March 2023 Day 1 Workshops W1 Vaccines for special populations Ruth Karron, Johns Hopkins U. and Carolyn Deal, NIAID (chairs) 14:00 - 15:30 Grand Ballroom (West Tower) Arnaud Didierlaurent, U. Geneve Vaccines for special populations: Immunological considerations Anna Seale, BMGF Group B Streptococcus Vaccination in Pregnant Women Mindy Miner, Fred Hutchinson CRI TB Vaccine Roadmap for People Living with HIV Tarun Saluja, IVI COVID-19 vaccine effectiveness in the elderly population W2 Novel vaccine platforms Sue Ann Clemens, Oxford U. and Max Silverman, BMGF (chairs) 14:00 - 15:30 Grand Salon I&II (West Tower) Lynda Stuart, BioNTech Post-pandemic innovations in mRNA vaccines Nathalie Garcon, N3J Consulting mRNA and adjuvants: friends or foes ? Harry Kleanthous, SK Bioscience Nanoparticle vaccines, a success story for viral vaccine development Jerry Sadoff, Janssen New Developments in Viral Vector Vaccines W3 Regional manufacturing perspectives and opportunities Martin Friede, WHO (chair) 14:00 - 15:30 East Salon AB (East Tower) Nicaise Ndembi, African Union Patrick Tippoo, AVMI An African Mission - Establish and Sustain Mahima Datla, Biological E. Ltd Marta Tufet, Gavi Alliance Melanie Saville, CEPI Gavi s Strategy to Support Regional Manufacturing Updates and additional details at https://eventmobi.com/gvirf2023 Meeting materials and videos will be posted at https://www.technet-21.org/en/topics/gvirf Questions? Contact GVIRF@who.int 3
Global Vaccine and Immunization Research Forum 2023 Grand Hyatt, Incheon, Republic of Korea 28 30 March 2023 Day 2 Plenary Sessions Grand Ballroom (West Tower) Introduction to Day 2 Peter Dull, BMGF (chair) 08:30 - 08:45 Keynote 2: Hee-Chang Jang, National Institute of Health, Korea Future Pandemic R&D preparedness in Korea Jerome Kim, IVI Translating pandemic R&D learnings into the broader global health agenda 08:45 - 09:15 P4 Quantifying the value of vaccines beyond mortality Mark Jit, London School of Hygiene and Tropical Medicine (LSHTM, chair) Mark Jit, LSHTM - The Full Value of Vaccines Assessment (FVVA) concept Richard White, LSHTM Using the FVVA framework to estimate the potential health and economic impacts of novel TB vaccines in low- and middle-income countries David Bloom, Harvard U.* FVVA for Group A Streptococcus vaccines Jean-Pierre Amorij, UNICEF Exploring the potential of measles rubella microarray patches to reach zero dose children and improve measles vaccine coverage through an initial Full Value Vaccine Assessment Additional panelists: Alejandro Cravioto, Universidad Nacional Aut noma de M xico (UNAM); Ghassan Dbaibo, American University of Beirut; Bill Hausdorff, PATH; Rudzani Muloiwa, U. of Cape Town; and Marta Tufet, Gavi 09:15 - 10:45 10:45 - 11:15 Break Concurrent workshops see next page 11:15 - 12:45 Lunch Ballroom ABC (East Tower) 12:45 - 14:00 Workshop Reports Melanie Saville, CEPI W4 Mucosal immunity and vaccines Jessica Martinez, BMGF W5 Vaccine Development Strategies at the Intersection of Market Model, Value Drivers, and Access Policy Kwaku Poku Asante, Kintampo HRC W6 Implementation research to inform immunization programs 14:00 - 14:15 P5 Innovating to find and reach Zero-Dose Children Samir Sodha, WHO (chair) C. Edson Utazi, U. of Southampton Mapping the distribution of zero-dose children and their characteristics in low- and middle-income countries Abdul Momin Kazi, Aga Kahn University Using mHealth Interventions to Improve Vaccination Coverage Melkamu Ayalew, Ministry of Health, Ethiopia* Strengthening Routine Immunization: Use of Reaching Every District - Quality Improvement (RED-QI) approach Additional panelists: Jon Abramson, Wake Forest U. and Aboubacar Kampo, UNICEF 14:15 - 15:45 15:45 - 16:15 Break P6 Vaccine technologies for equity Philippe-Alexandre Gilbert, BMGF and Hun Kim, SK BIO (chairs) Jean-Pierre Amorij, UNICEF The Vaccine Innovation Prioritisation Strategy (VIPS): driving innovations to improve vaccine delivery in low- and middle-income countries Mathias Garny, Univercells* A low footprint vaccine manufacturing platform for in-country, for-country production Ana Jaklenec, Massachusetts Institute of Technology (MIT)* Single injection vaccines Rachel Park, Eubiologics EuBiologics s Vaccine Technologies for Equity Additional panelists: Baik-Lin Seong, Vaccine Innovative Technology Alliance (VITAL)-Korea; Jae Myun Lee, Yonsei U.; and Rino Rappuoli, Fondazione Biotecnopolo di Siena 16:15 - 17:45 17:45 - 18:30 Break Reception and Poster session 2 (even-numbered posters) Peter Dull, BMGF (chair) EunKyoung Shin, Korean Ministry of Health and Welfare and Hani Kim, RIGHT Foundation 18:30 - 19:30 4
Global Vaccine and Immunization Research Forum 2023 Grand Hyatt, Incheon, Republic of Korea 28 30 March 2023 Day 2 Workshops W4 Mucosal immunity and vaccines Melanie Saville, CEPI (chair) Peter Openshaw, Imperial College of London Mucosal Immunity: What s special about it and can vaccines induce it? Michael Egan, CastleVax A Mucosally-delivered Newcastle Disease Virus-vectored Booster Vaccine to Prevent SARS-CoV-2 Breakthrough Infection and Transmission Chunlin Xin, CanSino Adenovirus Vector Based Covid-19 Inhalation Vaccine Darin Edwards, Moderna mRNA-lipid nanoparticle vaccines for intranasal delivery Additional panelists: Ryan Thwaites, Imperial College of London Peter Andersen, Novo Nordisk Foundation A translational Research Institute focused on vaccines and airway immunity 11:15 - 12:45 Grand Ballroom (West Tower) W5 Vaccine development strategies at the intersection of market model, value drivers, and access policy Jessica Martinez, BMGF and Raman Rao, Hilleman Laboratories (chairs) Jessica Martinez, BMGF Introduction: Our Burning Platform Kasturi Rangan, Harvard University* Business at the Base of the Income Pyramid Alice Chen, University Southern California The Next Frontier in Defining Value: Health Economics in Low- and Middle-Income Countries Hani Kim, RIGHT Foundation Developing vaccines as global public good: RIGHT foundation s approach Additional panelists: Lynda Stuart, BioNTech Jin Park, SK Bioscience Rachel Park, Eubiologics Yi Wang, National University of Singapore 11:15 - 12:45 Grand Salon I&II (West Tower) W6 Implementation research to inform immunization programs Kwaku Poku Asante, Kintampo Health Research Centre (chair) Alexander Rowe, US Centers for Disease Control and Prevention What is implementation research and why is it important? Halidou Tinto, Institute of Research in Health Sciences Implementation research needs on malaria vaccine delivery according to epidemiological context Cathy Ndiaye, PATH Reaching adolescent girls with the HPV vaccine Jessica Fleming, PATH* Protecting young infants through immunoprevention Additional panelists: Mary Hamel, WHO Marta Tufet, Gavi Alliance 11:15 - 12:45 East Salon AB (East Tower) *recorded presentation Updates and additional details at https://eventmobi.com/gvirf2023 Meeting materials and videos will be posted at https://www.technet-21.org/en/topics/gvirf Questions? Contact GVIRF@who.int 5
Global Vaccine and Immunization Research Forum 2023 Grand Hyatt, Incheon, Republic of Korea 28 30 March 2023 Day 3 Plenary Sessions Grand Ballroom (West Tower) Introduction to Day 3 Martin Friede, WHO (chair) 08:30 - 08:45 P7 Optimizing vaccine regimens Kristen Earle, BMGF and Andrew Pollard, Oxford U. (chairs) Naor Bar-Zeev, WHO* Optimizing immunization schedules Andrew Pollard, Oxford U. Impact on immunogenicity: dose, schedule and platform Deborah Watson-Jones, LSHTM Optimizing vaccine regimens Human papillomavirus 1-dose Rudzani Muloiwa, U. Cape Town Timing of South Africa's PCV and Measles infant doses: Considerations on the adoption of a vaccine schedule Additional panelist: Narendra Arora, INCLEN 08:45 - 10:15 10:15 - 10:45 Break 10:45 - 12:15 Concurrent workshops see next page 12:15-12:30 Reassemble in the Grand Ballroom (West Tower) for closing sessions Workshop Reports Shahida Baqar, NIH/NIAID and Alejandro Cravioto, UNAM W7 New vaccines on the horizon Sinead Delany-Moretlwe, U. of the Witwatersrand and Peter Dull, BMGF W8 Select poster highlights Lisa Menning, WHO W9 Addressing low uptake 12:30 - 12:45 P8 Reflections and closing remarks: Progress and the path forward Noni MacDonald, Dalhousie U. (chair) KP Asante, Kintampo HRC Kevin Kee-Jong Hong, Gachon U. Mark Jit, LSHTM Julie Leask, U. of Sydney 12:45 - 13:45 13:45 Close of meeting - lunch available following the close *recorded presentation Updates and additional details at https://eventmobi.com/gvirf2023 Meeting materials and videos will be posted at https://www.technet-21.org/en/topics/gvirf Questions? Contact GVIRF@who.int 6
Global Vaccine and Immunization Research Forum 2023 Grand Hyatt, Incheon, Republic of Korea 28 30 March 2023 Day 3 Workshops W7 New vaccines on the horizon Shahida Baqar, NIH/NIAID and Alejandro Cravioto, UNAM (chairs) Annelies Wilder-Smith, WHO Dengue Vaccine Development Ruth Karron, Johns Hopkins U. 2023: the year of RSV Michelo Simuyandi, Centre for Infectious Disease Research, Zambia* Enteric Disease: Shigella and ETEC Vaccine Development Additional panelists: Fred Cassels, PATH; Kirsty Le Doare, Makerere University Johns Hopkins University Research Collaboration 10:45 - 12:15 Grand Ballroom (West Tower) W8 Select poster highlights Sinead Delany-Moretlwe, U. of the Witwatersrand and Peter Dull, BMGF (chairs) 43. Hitt Sharma, Serum Institute of India Changing the HPV landscape with indigenous vaccine CERVAVAC 24. Debasu Damtie Gella, U. Gondar High prevalence of rotavirus infection among under five children despite a high rotavirus vaccination coverage in Ethiopia 16. Dal-Hee Min, Lemonex Inc. Innovative DDS DegradaBALL for mRNA vaccine against next pandemics: 100 days mission 32. Mohammad Mamun Alam, ICDDR,B Cross-neutralization of Influenza A by SARS-CoV-2 antibodies 8. Chul Kim, Progeneer Inc. Nucleoprotein Antigen Adjuvanted with Liposomal Cholesterol-linked TLR7/8 Agonist Showed Protective Immunity in Influenza Mouse Model 22. Josphat Kosgei, USAMRU RV 460 Study: Comparative Adjuvant Study for HIV Env-C DNA and Protein Vaccines in Kenya 20. Timothy Chege, KEMRI Wellcome Trust The landscape of infectious disease exposure over the past two decades in the Kenyan coast 4. Chang-Yuil Kang, Cellid Polyvalent strategy to the development of broadly protective vaccines against COVID-19 subvariants Poster abstracts available at https://www.technet-21.org/en/topics/gvirf 10:45 - 12:15 Grand Salon I&II (West Tower) W9 Understanding and addressing low uptake: a behavioral and social science perspective Lisa Menning, WHO (chair) Julie Leask, U. of Sydney Vaccine uptake and equity: how to understand and address low uptake? Interactive exercise: Vaccination behaviors in practice Amaya Gillespie, UNICEF Applying Social Science & Behavioural Design in Development and Humanitarian settings: Middle East & North Africa Hadley Ikwe, CDC Nigeria Use of Social data to inform programmatic action for COVID-19 vaccine uptake in Nigeria 10:45 - 12:15 East Salon AB (East Tower) *recorded presentation Updates and additional details at https://eventmobi.com/gvirf2023 Meeting materials and videos will be posted at https://www.technet-21.org/en/topics/gvirf Questions? Contact GVIRF@who.int 7
Global Vaccine and Immunization Research Forum 2023 Grand Hyatt, Incheon, Republic of Korea 28 30 March 2023 Posters 1 Hyeon Kim Development of a next generation vaccine using novel gut microbes External laboratory validation of the Bioneer Q-RFIA PCR kit on IRON qPCR for the MTBC and resistance detection Tissue-resident CD4+ T helper cells assist the development of protective respiratory B and CD8+ T cell memory responses Polyvalent strategy to the development of broadly protective vaccines against COVID-19 subvariants 2 Jong Seok Lee 3 Young Min Son 4* Chang-Yuil Kang Jung-Hwan Park 5 Development of platform for COVID-19 vaccine microneedles A Green Technology for Inactivated Vaccine: EGCG (Epigallocatechin-3-gallate)- Inactivated Zika Virus Vaccine Fast delivery of low-cost RSV vaccine platform: Chaperna-based bacterial production of pre- fusion stabilized RSV F protein nanoparticle vaccine Nucleoprotein Antigen Adjuvanted with Liposomal Cholesterol-linked TLR7/8 Agonist Showed Protective Immunity in Influenza Mouse Model 6 Jae Myun Lee 7 Jina Ahn 8* Chul Kim Hyuk-Joon Kwon 9 Engineering optimal live H1N1 vaccine strains by tuning PB2 activity 10 Hyungil Jung Delivery Technology for Microneedle Transdermal Vaccination Administration of antigen-loaded dendritic cells increases the immunogenicity of BCG via promoting the formation of lung-resident memory T cells and inducible bronchus- associated lymphoid tissues Adjunctive adjuvant effect of c-di-GMP on immunogenicity of TLR4-adjuvanted tuberculosis subunit vaccine 11 Hongmin Kim Kee Woong Kwon 12 13 Beom-Jin Lee A fattigation of virus vaccine antigen with fatty acid for enhanced thermal stability Effects of cholesterol depletion on extracellular vesicles released from dying cells by apoptosis Proof of concept of extracellular vesicles expressing SARS-CoV-2 structural proteins as a potential vaccine candidate Innovative DDS DegradaBALL for mRNA vaccine against next pandemics: 100 days mission' In silico analysis of protein-protein interaction networks between humans and Plasmodium falciparum for the design of vaccine candidates The characteristics of interventional clinical trials in Uganda; a cross-sectional study of registered clinical trial at the clinical trial.gov registry Serological survey to identify the susceptibility to wild-type measles among infants at 4 and 9 months of age, in Ghana An analysis of the sero-epidemiological signatures of vaccine and non-vaccine targets in a cohort of Kenyan infants Immunization against tetanus during pregnancy and newborn protection: Serological investigation for maternal and neonatal antibodies in Bobo Dioulasso, Burkina Faso 14 Junho Kim Tamanna Mustajab 15 16* Dal-Hee Min Fatoumata Gnine Fofana 17 18 Mwaka Joseph Isabela Garrido da S. Gonzalez 19 20* Chege T. Kuria Frederic Nikiema 21 Join Reception 1 to discuss odd-numbered posters and Reception 2 to discuss even-numbered posters. Abstracts available online at https://www.technet-21.org/en/hot-topics-items/15105-gvirf * Poster will be presented in Workshop 8. 8
Global Vaccine and Immunization Research Forum 2023 Grand Hyatt, Incheon, Republic of Korea 28 30 March 2023 Posters RV 460 Study: Comparative Adjuvant Study for HIV Env-C DNA and Protein Vaccines in Kenya Discovery of a Novel Leptospirosis-Secreted Exotoxin that Mediates Pathogenesis: Clinical Translation to a Pan-Leptospirosis Vaccine High prevalence of rotavirus infection among under five children despite a high rotavirus vaccination coverage in Ethiopia Landscaping analysis of immunization progress and program structures in selected middle-income Southeast Asian countries SARS-CoV-2 and dengue coinfection in Filipino children: epidemiology profile, clinical presentation and outcomes Why is Pakistan trailing behind in the implementation of childhood immunization: Inequalities between two South Asian Countries, Pakistan, and Bangladesh. Assessment of Health Care Workers Preparedness to Epidemics: Case of Ebola Virus Disease Preparedness in Private Hospitals in Kampala, Uganda Improving COVID -19 Vaccine uptake through the provision of integrated health services: Results from KNCV Nigeria USAID funded COVID-19 Vaccination Acceleration Project Impact of the COVID-19 pandemic on routine vaccination uptake in Kenya: an analysis of coverage of pentavalent and measles-rubella vaccines Assessing determinants of zero-dose children and guiding the efforts to serve them two proposed frameworks Cross-neutralization of Influenza A by SARS-CoV-2 specific neutralizing antibodies and polyclonal plasma: Is pre-exposure to SARS-CoV-2 protective against Influenza A? Characterization of carbapenem-producing Enterobacterales from untreated water from Nairobi River, Wastewater Treatment Plant and Slaughterhouse in Nairobi, Kenya Robust Heterologous Booster Response after Half dose of SCB-2019 in CoronaVac 3-dose immunized adults Superior Immune Response after Heterologous boosting of CoronaVac 2-dose or 3-dose immunized adults with SCB-2019 Understanding Structural Barriers to Vaccine Access among the Transgender and Disability Communities: Evidence from a Photovoice Stories Study in India Acceptability of the Reduced Dose Strategy of the Human Papillomavirus (HPV) Vaccine Among Healthcare Providers in Kenya Barriers and Facilitators of the Human Papillomavirus (HPV) Vaccine Delivery in Kenya 22* Josphat Kosgei Reetika Chaurasia 23 24* Debasu Damtie Jessabelle E. Basa Francesca Mae T. Pantig 25 26 27 Rabia Saleem Collins Ankunda Bethrand Odume 28 29 30 Michael Ngigi 31 Onei Uetela Mohammad Mamun Alam 32* 33 J. R. Too 34 Htay Htay Han 35 Igor Smolenov 36 Sharin Dsouza 37 Grace Umutesi 38 Lynda M. Oluoch 39 Balla Diarra Management and Administration of Malaria Vaccine Candidates during Clinical Trials in Mali Leveraging QGIS and Data analytics to identify, strategize and reach zero dose children in Cameroon. Facilitators to COVID-19 vaccine uptake among rural adult population in Lilongwe rural, Malawi Clinical trial capacity building in a pandemic outcome of a rapid site readiness project in Latin America 40 Yauba Saidu 41 Fanny Jumapili Sue Ann Costa Clemens 42 43* Hitt Sharma Changing the HPV landscape with indigenous vaccine CERVAVAC Join Reception 1 to discuss odd-numbered posters and Reception 2 to discuss even-numbered posters. Abstracts available online at https://www.technet-21.org/en/hot-topics-items/15105-gvirf * Poster will be presented in Workshop 8. 9
